{"entity":{"id":"zbtb16","kind":"target","name":"ZBTB16","aka":["zinc finger and BTB domain containing 16","Zinc finger and BTB domain-containing protein 16","ZNF145"],"tldr":"ZBTB16 (Zinc finger and BTB domain-containing protein 16) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Prostate cancer, Oesophageal cancer, Skin cancer and 4 more.","summary":"Acts as a transcriptional repressor. Transcriptional repression may be mediated through recruitment of histone deacetylases to target promoters. May play a role in myeloid maturation and in the development and/or maintenance of other differentiated tissues.\n\nOpen Targets scores its association with cancer at 0.72 (direct and indirect evidence; datatypes affected pathway 0.61, literature 0.98, genetic association 0.43, somatic mutation 0.84, animal model 0.64). IntOGen calls it a driver in 2 cohorts (1 activating, 1 loss-of-function), covering Oesophageal Squamous Cell Carcinoma, Prostate Adenocarcinoma.","asOf":"2026-09-23","links":[{"label":"HGNC HGNC:12930","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:12930"},{"label":"UniProt Q05516","url":"https://www.uniprot.org/uniprotkb/Q05516/entry"},{"label":"NCBI Gene 7704","url":"https://www.ncbi.nlm.nih.gov/gene/7704"},{"label":"Ensembl ENSG00000109906","url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000109906"}],"tags":["cancer-genes-wave"],"related":["open-targets","intogen"],"cancers":["prostate","esophageal","skin-cancer","breast-cancer","lung-cancer","oesophageal-squamous-cell-carcinoma","melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-robinson-integrative-clinical-genomics-advanced-prostate-cell-2015","paper-stopsack-prostate-genomes-by-race-ccr-2022"],"journals":[],"dependsOn":[],"notes":["Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 1 cohort; IntOGen calls it a loss-of-function (LoF) driver in 1 cohort; UniProt disease notes describe a translocation or gene fusion involving the gene. Evidence tier \"cohort-driver\" is the strongest of those signals.","Prevalence not recorded: none of the sources gives a positivity rate."],"provenance":{"editedBy":"scripts/fetch-cancer-genes.ts (CIViC, Open Targets, IntOGen, HGNC, UniProt)","editedOn":"2026-09-23"},"symbol":"ZBTB16","role":["oncogene-driver","tumour-suppressor","fusion-partner"],"evidenceTier":"cohort-driver","sources":[{"label":"HGNC HGNC:12930","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:12930","note":"approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)"},{"label":"UniProt Q05516","url":"https://www.uniprot.org/uniprotkb/Q05516/entry","note":"protein name, function text, keywords and locations (REST API)"},{"label":"Open Targets ENSG00000109906","url":"https://platform.opentargets.org/target/ENSG00000109906/associations","note":"association with cancer (MONDO_0004992) 0.72; per-cancer scores at or above 0.5: prostate cancer 0.51, melanoma 0.52, skin cancer 0.55, breast cancer 0.53, lung cancer 0.52 (GraphQL API, CC0)"},{"label":"IntOGen ZBTB16","url":"https://www.intogen.org/search?gene=ZBTB16","note":"driver in 2 cohorts (Act 1, LoF 1); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0"}],"specificitySources":[],"hgnc":"HGNC:12930","ensembl":"ENSG00000109906","uniprot":"Q05516","entrez":"7704","firstDescribed":1993,"firstDescribedBasis":"sequence","firstDescribedNote":"Earliest sequence paper UniProt cites for the protein: Chen et al, EMBO J, 1993, \"Fusion between a novel Kruppel-like zinc finger gene and the retinoic acid receptor-alpha locus due to a variant t(11;17) translocation associated with acute promyelocytic leukaemia\".","firstDescribedSource":"https://pubmed.ncbi.nlm.nih.gov/8384553/","biology":"Acts as a transcriptional repressor. Transcriptional repression may be mediated through recruitment of histone deacetylases to target promoters. May play a role in myeloid maturation and in the development and/or maintenance of other differentiated tissues. Probable substrate-recognition component of an E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins. Location: Nucleus; Nucleus, nuclear body (UniProt). Locus 11q23.2 (HGNC).","whereFound":["Prostate cancer: Open Targets association 0.51 with prostate cancer (MONDO_0008315); IntOGen driver in 1 cohort (PRAD)","Oesophageal cancer: IntOGen driver in 1 cohort (ESCC)","Skin cancer: Open Targets association 0.55 with skin cancer (MONDO_0002898)","Breast cancer: Open Targets association 0.53 with breast cancer (MONDO_0007254)","Lung cancer: Open Targets association 0.52 with lung cancer (MONDO_0008903)","Oesophageal squamous cell carcinoma: IntOGen driver in 1 cohort (ESCC)","Prostate cancer: deletion or truncating mutation 1-9% depending on disease state"],"targetClass":"transcription","prevalence":[{"cancerId":"prostate","pct":"1-9","measure":"Deletion or truncating mutation","source":"https://www.cbioportal.org/study/summary?id=prad_p1000","note":"cBioPortal ZBTB16 deep deletion: 43 of 1,013, 4.2%, in prad_p1000; 17 of 489, 3.5%, in prad_tcga_pan_can_atlas_2018; 13 of 444, 2.9%, in prad_su2c_2019; 8 of 150, 5.3%, in prad_su2c_2015. ZFHX3 mutation: 142 of 2,260, 6.3%, in prostate_msk_2024; 22 of 444, 5.0%, in prad_su2c_2019, with deep deletion 29 of 489, 5.9%, in prad_tcga_pan_can_atlas_2018."}]},"route":"/targets/zbtb16/","neighbours":{"collection":[{"id":"intogen","kind":"collection","name":"IntOGen","route":"/collections/intogen/"},{"id":"open-targets","kind":"collection","name":"Open Targets Platform","route":"/collections/open-targets/"}],"cancer":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/"},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"esophageal","kind":"cancer","name":"Oesophageal cancer","route":"/cancers/esophageal/"},{"id":"oesophageal-squamous-cell-carcinoma","kind":"cancer","name":"Oesophageal squamous cell carcinoma","route":"/cancers/oesophageal-squamous-cell-carcinoma/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"},{"id":"skin-cancer","kind":"cancer","name":"Skin cancer (all types)","route":"/cancers/skin-cancer/"}],"paper":[{"id":"paper-stopsack-prostate-genomes-by-race-ccr-2022","kind":"paper","name":"Differences in prostate cancer genomes by self-reported race","route":"/key-papers/paper-stopsack-prostate-genomes-by-race-ccr-2022/"},{"id":"paper-robinson-integrative-clinical-genomics-advanced-prostate-cell-2015","kind":"paper","name":"SU2C-PCF: integrative clinical genomics of advanced prostate cancer","route":"/key-papers/paper-robinson-integrative-clinical-genomics-advanced-prostate-cell-2015/"}]}}